Wall Street Zen upgraded shares of Cogent Biosciences (NASDAQ:COGT – Free Report) from a sell rating to a hold rating in a report published on Saturday morning.
COGT has been the topic of several other research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Cogent Biosciences in a research note on Wednesday, July 8th. Guggenheim upped their price objective on Cogent Biosciences from $45.00 to $52.00 and gave the stock a “buy” rating in a research report on Wednesday, August 12th. Wedbush reiterated an “outperform” rating and set a $55.00 price objective on shares of Cogent Biosciences in a report on Friday, May 29th. HC Wainwright increased their price objective on Cogent Biosciences to $55.00 and gave the stock a “buy” rating in a report on Wednesday, May 6th. Finally, Piper Sandler lifted their target price on Cogent Biosciences from $52.00 to $55.00 and gave the company an “overweight” rating in a research report on Monday, August 17th. Two analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $49.40.
Get Our Latest Analysis on Cogent Biosciences
Cogent Biosciences Trading Up 4.0%
Cogent Biosciences (NASDAQ:COGT – Get Free Report) last posted its quarterly earnings data on Monday, August 10th. The technology company reported ($0.52) EPS for the quarter, beating the consensus estimate of ($0.55) by $0.03. As a group, research analysts forecast that Cogent Biosciences will post -2.24 EPS for the current fiscal year.
Institutional Investors Weigh In On Cogent Biosciences
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Nykredit A S bought a new stake in Cogent Biosciences during the 2nd quarter worth about $159,000. Alyeska Investment Group L.P. boosted its stake in shares of Cogent Biosciences by 9.9% during the 2nd quarter. Alyeska Investment Group L.P. now owns 274,849 shares of the technology company’s stock worth $10,637,000 after buying an additional 24,849 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in shares of Cogent Biosciences by 26.5% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 209,402 shares of the technology company’s stock valued at $8,104,000 after acquiring an additional 43,892 shares in the last quarter. Wellington Management Group LLP grew its holdings in shares of Cogent Biosciences by 21.4% in the 2nd quarter. Wellington Management Group LLP now owns 4,343,977 shares of the technology company’s stock valued at $168,112,000 after acquiring an additional 765,355 shares in the last quarter. Finally, Empowered Funds LLC acquired a new stake in shares of Cogent Biosciences in the second quarter valued at about $278,000.
More Cogent Biosciences News
Here are the key news stories impacting Cogent Biosciences this week:
- Positive Sentiment: HC Wainwright maintained its “Buy” rating and $55 price objective for COGT, signaling confidence in Cogent Biosciences’ longer-term growth prospects. HC Wainwright analyst coverage
- Positive Sentiment: The analyst expects losses to narrow significantly in 2027, forecasting quarterly EPS of $(0.50), $(0.38), $(0.26), and $(0.15), resulting in a full-year loss of $(1.28). The improving trajectory may support the stock’s valuation if Cogent’s pipeline advances as expected. Cogent Biosciences 2027 earnings estimates
- Neutral Sentiment: HC Wainwright initiated its 2027 estimates, including a $(1.28) full-year EPS forecast. These projections provide new expectations for investors but do not represent a change to the company’s operating results. Cogent Biosciences analyst estimates
- Negative Sentiment: HC Wainwright reduced its 2026 EPS forecasts, lowering Q3 estimates to $(0.59) from $(0.56), Q4 estimates to $(0.62) from $(0.57), and full-year estimates to $(2.37) from $(2.21). The revisions indicate higher expected losses in the near term and could limit upside despite the bullish rating. Cogent Biosciences 2026 earnings estimate revisions
Cogent Biosciences Company Profile
Cogent Biosciences is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that modulate the tumor microenvironment. The company’s research centers on targeting colony-stimulating factor 1 receptor (CSF1R), a key regulator of tumor-associated macrophages that can promote tumor growth and immune evasion. By selectively inhibiting CSF1R, Cogent Biosciences aims to restore immune surveillance and enhance the efficacy of existing cancer treatments.
The company’s lead asset is an orally bioavailable CSF1R inhibitor that has advanced into early-stage clinical trials for various solid tumors.
Read More
- Five stocks we like better than Cogent Biosciences
- 2 Biotech Stocks Shaping Up for Major Breakouts
- 3 Stocks Came Roaring Back—Now They’re Flashing Warning Signs
- 3 Beaten-Down Stocks That Haven’t Gotten the Message About the S&P 500’s Record Run
- Darden Restaurants Just Hit a 52-Week High–Is the Olive Garden Comeback Story Legit?
Receive News & Ratings for Cogent Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cogent Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
